Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MUC1 and cancer.

J Taylor-Papadimitriou1, J Burchell, D W Miles

  • 1Imperial Cancer Research Fund, Breast Cancer Biology Group, Guy's Hospital, London, UK.

Biochimica Et Biophysica Acta
|November 26, 1999
PubMed
Summary

MUC1, a cancer-associated molecule, differs from normal mucin due to altered glycosylation. These changes expose unique epitopes, making MUC1 a target for cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening Criteria in Breast Cancer Trials: Are They Too Restrictive?

Clinical oncology (Royal College of Radiologists (Great Britain))·2015
Same author

Predicting distress among people who care for patients living longer with high-grade malignant glioma.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2015
Same author

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.

British journal of cancer·2013
Same author

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

British journal of cancer·2013
Same author

Cellular transformation by chemicals and oncogernes gene transfer and phenotypic changes.

Cytotechnology·2012

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • MUC1 is a membrane mucin identified by antibodies targeting epithelial cells and cancers.
  • Its extracellular domain consists of conserved amino acid repeats, with glycosylation sites influencing antigenicity.

Purpose of the Study:

  • To investigate the antigenic differences between normal and cancer-associated MUC1.
  • To explore the potential of MUC1 as a target for cancer immunotherapy.

Main Methods:

  • Gene cloning to analyze MUC1 structure.
  • Glycosylation analysis of MUC1 from normal and cancerous breast tissue.
  • Review of immune responses and clinical studies involving MUC1.

Main Results:

  • MUC1 from normal breast tissue has complex, core 2-based O-glycans.
  • Breast cancer MUC1 exhibits mainly core 1-based O-glycans, exposing protein epitopes.
  • Novel carbohydrate epitopes are present on cancer-associated MUC1, rendering it antigenically distinct.

Conclusions:

  • MUC1's altered glycosylation in cancer creates unique epitopes, distinguishing it from normal MUC1.
  • These antigenic differences support MUC1's role as a target for cancer immunotherapy.
  • The role of MUC1 carbohydrates in immune responses warrants further investigation.

Related Experiment Videos